



**Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **Deborah K. Armstrong, M.D.**

Committee: **Oncologic Drugs Advisory Committee**

Meeting Date: **February 9, 2021**

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: *Pembrolizumab for the treatment of patients with high-risk, early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then as a single agent as adjuvant treatment after surgery*, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
None		
<b>II. Other Imputed Interests</b>		
Contract/grant	Translational Research In Oncology (TRIO; unrelated entity), University of California, Los Angeles (competing entity), and product at issue.	\$0 – 50,000 per year to Johns Hopkins University  \$0 – 5,000 per year in salary support to Dr. Armstrong
Contract/grant	Merck Sharp & Dohme, a subsidiary of Merck & Co. (sponsor), University of Virginia (unrelated entity), and product at issue.	\$0 – 50,000 per year to Johns Hopkins University  \$0 – 5,000 per year in salary support to Dr. Armstrong

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/s/  
Signature

\_\_\_\_\_/1/21/2021  
Date